Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma

Yao, Min; Yao, Dengfu; Bian, Yinzhu; Wu, Wei; Yan, Xiaohui; Yu, Dandan; Qiu, Liwei; Yang, Junling; Zhang, Haijian; Wang, Sai; Chen, Jie

doi:10.1016/s1499-3872(13)60028-4

Cited by 41 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HCCs express Afp and Gpc3 mRNA (16,17), and immunostain positively for GST-P and HSP-70 of HCC (18,19). These observations support the hypothesis that the liver tumors observed in STAM-F mice were HCCs.…”

Section: Discussionsupporting

confidence: 71%

Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Abstract. The molecular mechanisms underlying the progression of nonalcoholic steatohepatitis (NASH) have not been fully elucidated. The aim of this study was to identify factors involved in NASH progression by analysis of pathophysiological features and gene-expression profiles in livers of STAM mice, a model of NASH-associated hepatocarcinogenesis. C57BL/6N (B6N) mice were injected with streptozotocin to generate STAM mice. Four-week-old male STAM and B6N

show abstract

Section: Discussionsupporting

confidence: 71%

Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In this study, we indeed observed an elevation in diagnostic sensitivity (72.8%) when GPC3 was combined with AFP, and several previous studies also clearly stated that GPC3 could be complementary to AFP and provide elevated sensitivity for the diagnosis of HCC. 8,[18][19][20] In this study, the clinical characteristics of patients with HCC, including HBV infection, Child-Pugh score, number of tumors, tumor size, tumor stage, and portal vein invasion, were also evaluated. No statistical association was observed between serum GPC3 and these clinical characteristics, which indicated no prognostic value of serum GPC3 for HCC.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma

Jia

Gao

Zhai

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

Glypican-3 has been reported to be one of the most promising serum markers for hepatocellular carcinoma. This study aimed to assess the clinical utility of serum glypican 3 for the diagnosis of hepatocellular carcinoma. We recruited consecutive patients on a large scale, 283 with hepatocellular carcinoma, 445 with chronic hepatic diseases, and 162 normal controls, to assess the diagnostic accuracy of serum glypican 3 for hepatocellular carcinoma by enzyme-linked immunosorbent assay. In addition, we further analyzed the relationship between the serum levels of a-fetoprotein and glypican-3 in patients with hepatocellular carcinoma. The results indicated that serum glypican 3 was elevated in patients with hepatocellular carcinoma (0 ng/mL, range ¼ 0-14.0 ng/mL, P ¼ .033) and liver cirrhosis (0 ng/mL, range ¼ 0-12.5 ng/mL, P ¼ .001) compared to the levels in normal control (0 ng/mL, range ¼ 0-4.3 ng/mL), but there was no difference between hepatocellular carcinoma and liver cirrhosis (P ¼ .097). The area under the curve of the receiver-operating characteristics curve for hepatocellular carcinoma versus all controls was 0.519, with a sensitivity of 39.9%, a specificity of 60.6%, and an optimal cutoff value of 0.002 ng/mL. The positive and negative predictive values were 32.0% and 68.3%, respectively. No significant correlation in serum levels was observed between glypican 3 and a-fetoprotein (P > .05). The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with a-fetoprotein. Glypican 3 was not a promising serum maker for the diagnosis of hepatocellular carcinoma alone, but it could be complementary to a-fetoprotein and elevate the sensitivity of hepatocellular carcinoma diagnosis.

show abstract

“…4D), the heterogeneity among studies was moderate (I 2 = 28%, p=0.20). The RRs for Tumor number were available in 6 studies [22,27,[34][35][36]40], the estimated pooled RR showed a trend towards greater numbers of CTC with more tumor number, but they did not achieve statistical significance (p=0.07. Fig.…”

Section: Correlation Of Circulating Tumor Cells With Clinicopathologimentioning

confidence: 94%

Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis

Fan

Yang

Yuan

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The prognostic value of circulating tumor cells (CTC) detected in hepatocellular carcinoma (HCC) patients is currently under debate. We conducted a meta-analysis of available studies to assess its prognostic value for patients diagnosed with HCC. Methods: Medline, Ovid Database, Embase, The Science Citation Index, and Cochrane library, search was conducted on all studies reporting the outcomes of interest. The studies were set up according to the inclusion/exclusion criteria. Using a random-effects model, meta-analysis was performed using hazard ratio (HR), risk ratio (RR) and their 95% confidence intervals (95% CIs) as effect measures. Heterogeneity of the studies was tested for each pooled analysis. Subgroup and sensitivity analyses were also performed. Results: twenty-three published studies that matched the selection criteria were included in this meta-analysis. CTC positivity was significantly associated with Relapse free survival (RFS) (HR 3.03, 95% CI: [1.89-4.86]; p<0.00001) and Overall survival (OS) (HR 2.45, 95% CI: [1.73-3.48]; p<0.00001). CTC positivity were also significantly associated with TNM Stage (RR 1.30, 95% CI: [1.02-1.65]; p=0.03), Tumor size (RR 1.36, 95% CI: [1.09-1.69]; p=0.006), Vascular invasion (RR 1.99, 95% CI: [1.43-2.77]; p<0.0001), Portal vein tumor thrombus (RR 1.73, 95% CI: [1.42-2.11]; p=0.0001), Serum alpha-fetoprotein (AFP) level (RR 2.05, 95% CI: [1.18-3.54]; p=0.01). Conclusion: CTC positivity indicates poor prognosis in patients with hepatocellular carcinoma, and associated with poor clinicopathologic parameters.

show abstract

Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma

Cited by 41 publications

References 34 publications

Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma

Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis

Contact Info

Product

Resources

About